BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Recruiting now · Not applicable

Conditions studied: Squamous Cell Carcinoma

In brief

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

Key facts

Study ID
NCT06377735
Run by
Sun Yat-sen University
People needed
85
Starts
2024-05-01
Expected to finish
2026-12-30
Last updated by the study team
2024-08-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.